172 related articles for article (PubMed ID: 37909039)
21. Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN; Ashwood LM; Kondrashova O; Sutherland KD
Trends Cancer; 2023 Nov; 9(11):955-967. PubMed ID: 37591766
[TBL] [Abstract][Full Text] [Related]
22. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
23. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
24. A human immunoglobulin (Ig)A calpha3 domain motif directs polymeric Ig receptor-mediated secretion.
Hexham JM; White KD; Carayannopoulos LN; Mandecki W; Brisette R; Yang YS; Capra JD
J Exp Med; 1999 Feb; 189(4):747-52. PubMed ID: 9989991
[TBL] [Abstract][Full Text] [Related]
25. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
26. Signal transduction by the polymeric immunoglobulin receptor suggests a role in regulation of receptor transcytosis.
Cardone MH; Smith BL; Mennitt PA; Mochly-Rosen D; Silver RB; Mostov KE
J Cell Biol; 1996 Jun; 133(5):997-1005. PubMed ID: 8655590
[TBL] [Abstract][Full Text] [Related]
27. Dimeric IgA specifically disables intracellular mutated oncodrivers.
Prince S; Hollmén M
Immunity; 2023 Nov; 56(11):2461-2463. PubMed ID: 37967526
[TBL] [Abstract][Full Text] [Related]
28. Structural requirements for the interaction of human IgA with the human polymeric Ig receptor.
Lewis MJ; Pleass RJ; Batten MR; Atkin JD; Woof JM
J Immunol; 2005 Nov; 175(10):6694-701. PubMed ID: 16272325
[TBL] [Abstract][Full Text] [Related]
29. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
30. Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6.
van den Dobbelsteen ME; van der Woude FJ; Schroeijers WE; van den Wall Bake AW; van Es LA; Daha MR
Kidney Int; 1994 Aug; 46(2):512-9. PubMed ID: 7967365
[TBL] [Abstract][Full Text] [Related]
31. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
32. Sorting mechanisms regulating membrane protein traffic in the apical transcytotic pathway of polarized MDCK cells.
Gibson A; Futter CE; Maxwell S; Allchin EH; Shipman M; Kraehenbuhl JP; Domingo D; Odorizzi G; Trowbridge IS; Hopkins CR
J Cell Biol; 1998 Oct; 143(1):81-94. PubMed ID: 9763422
[TBL] [Abstract][Full Text] [Related]
33. KRAS
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Paradiso F; Sugimoto H; Arian KA; Ying H; Barekatain Y; Sthanam LK; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
Cancer Cell; 2023 Sep; 41(9):1606-1620.e8. PubMed ID: 37625401
[TBL] [Abstract][Full Text] [Related]
34. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
35. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
Keenan BP; Saenger Y; Kafrouni MI; Leubner A; Lauer P; Maitra A; Rucki AA; Gunderson AJ; Coussens LM; Brockstedt DG; Dubensky TW; Hassan R; Armstrong TD; Jaffee EM
Gastroenterology; 2014 Jun; 146(7):1784-94.e6. PubMed ID: 24607504
[TBL] [Abstract][Full Text] [Related]
36. Generation of polymeric immunoglobulin receptor-deficient mouse with marked reduction of secretory IgA.
Shimada S; Kawaguchi-Miyashita M; Kushiro A; Sato T; Nanno M; Sako T; Matsuoka Y; Sudo K; Tagawa Y; Iwakura Y; Ohwaki M
J Immunol; 1999 Nov; 163(10):5367-73. PubMed ID: 10553061
[TBL] [Abstract][Full Text] [Related]
37. Polymeric immunoglobin (Ig) receptor production and IgA transcytosis in polarized primary cultures of mature rat uterine epithelial cells.
Richardson JM; Kaushic C; Wira CR
Biol Reprod; 1995 Sep; 53(3):488-98. PubMed ID: 7578671
[TBL] [Abstract][Full Text] [Related]
38. Structural and biochemical requirements for secretory component interactions with dimeric Immunoglobulin A.
Kumar Bharathkar S; Stadtmueller BM
bioRxiv; 2024 Apr; ():. PubMed ID: 38014291
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor efficacy of a potent and selective non-covalent KRAS
Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
[TBL] [Abstract][Full Text] [Related]
40. Structural and Biochemical Requirements for Secretory Component Interactions with Dimeric IgA.
Kumar Bharathkar S; Stadtmueller BM
J Immunol; 2024 May; ():. PubMed ID: 38809110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
